| ELV |
Report |
Adjusted EPS (Q2 2026) |
BEAT |
pred ~$6.32 vs. cons $6.18 |
MEDIUM |
| ELV |
Report |
Benefit Expense Ratio (MLR) |
BEAT |
pred ~89.1% vs. cons 89.4% |
MEDIUM |
| ELV |
Report |
Total Operating Revenue |
IN-LINE |
pred ~$48.7B vs. cons $48.65B |
MEDIUM |
| ELV |
Guide |
FY2026 Adjusted EPS guidance |
UNCHANGED |
guide ~$26.75 vs. cons $26.75 (FY2026) |
MEDIUM |
| ELV |
Guide |
FY2026 Medicaid operating margin |
UNCHANGED |
guide ~-1.75% vs. cons -1.75% (FY2026) |
MEDIUM |
| ELV |
Guide |
FY2026 Medicare Advantage operating margin |
UNCHANGED |
guide ~2.0% vs. cons 2.0% (FY2026) |
LOW |
| ELV |
Guide |
CMS risk-adjustment accrual adequacy commentary |
UNKNOWN |
guide ~$935M accrual reaffirmed vs. cons $935M prior accrual (ahead of Jul 31, 2026 deadline) |
LOW |
| ELV |
Return |
Day-1 residual (stock − beta × S&P 500) |
-2.0% |
— |
MEDIUM |
| ELV |
Return |
5-day cumulative residual |
-3.5% (FADE) |
Stock has rallied ~43% into the print, so even a modest EPS/MLR beat is largely priced in; reaffirming (rather than raising) full-year EPS guidance implicitly raises the H2 bar given Q1's one-time investment income tailwind, and the unresolved CMS risk-adjustment deadline (Jul 31) plus lingering ACA morbidity/mix uncertainty (per HCA's exchange-mix warning) give bears a reason to fade an initial pop; expect analysts to trim numbers on H2 conservatism even after a Q2 beat, producing fade rather than follow-through. |
MEDIUM |